started · updated
Researchers identify potential blood biomarker for CTE diagnosis
Scientists at Washington University in St. Louis have identified a protein fragment, eMTBR-tau243, that may assist in diagnosing chronic traumatic encephalopathy (CTE) in living patients. Currently, CTE can only be confirmed through post-mortem brain tissue examination, as symptoms like memory loss and mood swings often overlap with other neurological conditions.
In a preliminary study, researchers analyzed blood samples from 11 individuals with confirmed CTE. They found that levels of the eMTBR-tau243 biomarker were higher in those with advanced CTE compared to healthy individuals, with concentrations rising alongside the severity of the disease. While the biomarker is also elevated in Alzheimer’s disease, the findings suggest it could eventually help clinicians monitor individuals at risk of developing the condition.
Experts caution that the findings are preliminary. The biomarker has not yet proven reliable for identifying early-stage CTE, and larger studies are required to validate its effectiveness. Researchers suggest the test would likely be used in conjunction with other diagnostic tools rather than as a standalone method.
Entities
Chihiro Sato · Kanta Horie · Northwestern University · Rudolph Castellani · Washington University in St. Louis